• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表达猿猴-人类免疫缺陷病毒89.6P包膜糖蛋白和猿猴免疫缺陷病毒mac239核衣壳蛋白的高度减毒狂犬病病毒疫苗载体在恒河猴中是安全的,并能预防类似艾滋病的疾病。

Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.

作者信息

McKenna Philip M, Koser Martin L, Carlson Kevin R, Montefiori David C, Letvin Norman L, Papaneri Amy B, Pomerantz Roger J, Dietzschold Bernhard, Silvera Peter, McGettigan James P, Schnell Matthias J

机构信息

Department of Microbiology, Thomas Jefferson University, Philadelphia, PA, USA.

出版信息

J Infect Dis. 2007 Apr 1;195(7):980-8. doi: 10.1086/512243. Epub 2007 Feb 20.

DOI:10.1086/512243
PMID:17330788
Abstract

We analyzed the safety and immunogenicity of attenuated rabies virus vectors expressing simian-human immunodeficiency virus (SHIV)-1(89.6P) Env or simian immunodeficiency virus (SIV)(mac239) Gag in rhesus macaques. Four test macaques were immunized with both vaccine constructs, and 2 control macaques received an empty rabies vector. Seroconversion against rabies virus glycoprotein (G) and SHIV(89.6P) Env was detected after the initial immunization, but no cellular responses against SHIV antigens were observed. HIV/SIV-specific immune responses were not enhanced by boosts with the same vectors. Therefore, we constructed vectors expressing SHIV(89.6P) Env and SIV(mac239) Gag in which the rabies G was replaced with the G protein of vesicular stomatitis virus (VSV). Two years after initial immunization, a boost with the rabies-VSV G vectors resulted in SIV/HIV-specific immune responses. Upon challenge with SHIV(89.6P) test macaques controlled the infection, whereas control macaques had high levels of viremia and a profound loss of CD4(+) T cells, with 1 control macaque dying of an AIDS-like disease.

摘要

我们分析了在恒河猴中表达猿猴-人类免疫缺陷病毒(SHIV)-1(89.6P)Env或猿猴免疫缺陷病毒(SIV)(mac239)Gag的减毒狂犬病病毒载体的安全性和免疫原性。四只受试恒河猴用两种疫苗构建体进行免疫,两只对照恒河猴接受空的狂犬病载体。初次免疫后检测到针对狂犬病病毒糖蛋白(G)和SHIV(89.6P)Env的血清转化,但未观察到针对SHIV抗原的细胞反应。用相同载体加强免疫并未增强HIV/SIV特异性免疫反应。因此,我们构建了表达SHIV(89.6P)Env和SIV(mac239)Gag的载体,其中狂犬病G被水泡性口炎病毒(VSV)的G蛋白取代。初次免疫两年后,用狂犬病-VSV G载体加强免疫引发了SIV/HIV特异性免疫反应。在用SHIV(89.6P)攻击后,受试恒河猴控制了感染,而对照恒河猴出现高病毒血症且CD4(+)T细胞大量减少,有一只对照恒河猴死于类似艾滋病的疾病。

相似文献

1
Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.表达猿猴-人类免疫缺陷病毒89.6P包膜糖蛋白和猿猴免疫缺陷病毒mac239核衣壳蛋白的高度减毒狂犬病病毒疫苗载体在恒河猴中是安全的,并能预防类似艾滋病的疾病。
J Infect Dis. 2007 Apr 1;195(7):980-8. doi: 10.1086/512243. Epub 2007 Feb 20.
2
Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.携带载体的Gag和Env而非Tat在Mamu - A*01阴性恒河猴中对猿猴 - 人类免疫缺陷病毒89.6P攻击显示出有效性。
J Virol. 2005 Oct;79(19):12321-31. doi: 10.1128/JVI.79.19.12321-12331.2005.
3
Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.编码猿猴免疫缺陷病毒gag基因和人类免疫缺陷病毒env基因的5型/35型嵌合腺病毒载体可使猴子对猿猴/人类免疫缺陷病毒产生保护性免疫。
Virology. 2007 Oct 25;367(2):390-7. doi: 10.1016/j.virol.2007.06.012. Epub 2007 Jul 12.
4
Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.在恒河猴SHIV模型中,使用重组env - gag - pol痘苗病毒安卡拉(MVA)疫苗策略并辅以或不辅以寡聚Env蛋白加强免疫的比较。
Virology. 2002 Mar 15;294(2):270-81. doi: 10.1006/viro.2001.1345.
5
The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.接种表达SIV Gag、Pol、Env和Nef蛋白的重组卡介苗活疫苗的恒河猴特异性免疫反应动力学。
Virology. 2000 Mar 1;268(1):94-103. doi: 10.1006/viro.1999.0131.
6
Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease.表达HIV-1和SIV抗原的脊髓灰质炎病毒复制子在食蟹猴中的免疫原性及对SHIV-89.6P疾病的保护作用。
Virology. 2003 Oct 25;315(2):425-37. doi: 10.1016/s0042-6822(03)00546-4.
7
Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.在SIVmac-猕猴模型中通过多基因DNA启动和腺病毒加强免疫降低病毒载量
Vaccine. 2006 Mar 10;24(11):1811-20. doi: 10.1016/j.vaccine.2005.10.026. Epub 2005 Oct 25.
8
Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).用两种不同减毒疫苗对猕猴进行序贯免疫可诱导长期的病毒特异性免疫反应,并对由异源猴免疫缺陷病毒(SHIV(89.6)P)引起的艾滋病提供保护。
Virology. 2001 Jan 5;279(1):241-56. doi: 10.1006/viro.2000.0695.
9
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.无复制能力的腺病毒疫苗载体可引发有效的抗免疫缺陷病毒免疫力。
Nature. 2002 Jan 17;415(6869):331-5. doi: 10.1038/415331a.
10
Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.通过接种多重基因缺失的猿猴免疫缺陷病毒(SHIV)疫苗,保护猕猴免受具有同源HIV-1包膜蛋白的SHIV以及具有异源包膜蛋白的致病性SHIV-89.6P的感染。
Virology. 1999 Dec 20;265(2):252-63. doi: 10.1006/viro.1999.0049.

引用本文的文献

1
Rabies virus as vector for development of vaccine: pros and cons.狂犬病病毒作为疫苗开发载体:利弊分析
Front Vet Sci. 2024 Sep 25;11:1475431. doi: 10.3389/fvets.2024.1475431. eCollection 2024.
2
Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.灭活狂犬病病毒载体 SARS-CoV-2 疫苗可预防叙利亚仓鼠模型中的疾病。
PLoS Pathog. 2021 Mar 25;17(3):e1009383. doi: 10.1371/journal.ppat.1009383. eCollection 2021 Mar.
3
Rhabdoviruses as vectors for vaccines and therapeutics.Rhabdoviruses 作为疫苗和治疗药物的载体。
Curr Opin Virol. 2020 Oct;44:169-182. doi: 10.1016/j.coviro.2020.09.003. Epub 2020 Oct 29.
4
A Zigzag but Upward Way to Develop an HIV-1 Vaccine.一条曲折但向上发展HIV-1疫苗的道路。
Vaccines (Basel). 2020 Sep 8;8(3):511. doi: 10.3390/vaccines8030511.
5
Replicon RNA Viral Vectors as Vaccines.复制子RNA病毒载体作为疫苗
Vaccines (Basel). 2016 Nov 7;4(4):39. doi: 10.3390/vaccines4040039.
6
Rhabdovirus-based vaccine platforms against henipaviruses.基于狂犬病毒的亨德拉尼帕病毒疫苗平台。
J Virol. 2015 Jan;89(1):144-54. doi: 10.1128/JVI.02308-14. Epub 2014 Oct 15.
7
Axonal and subcellular labelling using modified rabies viral vectors.使用改良的狂犬病毒载体进行轴突和亚细胞标记。
Nat Commun. 2013;4:2332. doi: 10.1038/ncomms3332.
8
Nonreplicating vectors in HIV vaccines.HIV 疫苗中的非复制型载体。
Curr Opin HIV AIDS. 2013 Sep;8(5):412-20. doi: 10.1097/COH.0b013e328363d3b7.
9
Development of replication-competent viral vectors for HIV vaccine delivery.用于 HIV 疫苗递送的复制型病毒载体的开发。
Curr Opin HIV AIDS. 2013 Sep;8(5):402-11. doi: 10.1097/COH.0b013e328363d389.
10
Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses.使用负链RNA病毒对针对1型人类免疫缺陷病毒Gag的异源初免-加强策略进行比较。
PLoS One. 2013 Jun 26;8(6):e67123. doi: 10.1371/journal.pone.0067123. Print 2013.